Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Josep M Llibre

Showing results (41-50 of 162) with videos related to

Pageof 17
Sort By:
AIDS Research and Human Retroviruses|December 1, 2010
Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patientsJosé R Santos, Josep M Llibre, Pere Domingo, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|April 11, 2016
Hepatic safety of maraviroc in HIV-1-infected patients with hepatitis C and/or B co-infection. The Maraviroc Cohort Spanish GroupManuel Crespo, Jordi Navarro, Santiago Moreno, et al.
AIDS (London, England)|June 16, 2011
Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapyJosep M Llibre, José R Arribas, Pere Domingo, et al.
AIDS Research and Human Retroviruses|June 9, 2009
How much fat loss is needed for lipoatrophy to become clinically evident?Daniel Podzamczer, Elena Ferrer, Esteban Martínez, et al.
AIDS Reviews|March 18, 2009
HIV-1 genotypic drug resistance interpretation rules - 2009 Spanish guidelinesCarmen de Mendoza, Lourdes Anta, Federico García, et al.
AIDS Research and Human Retroviruses|January 20, 2016
Short Communication: Efficacy and Safety of Treatment Simplification to Lopinavir/Ritonavir or Darunavir/Ritonavir Monotherapy: A Randomized Clinical TrialJosé R Santos, Josep M Llibre, Isabel Bravo, et al.
AIDS (London, England)|November 8, 2017
Initial treatment response among HIV subtype F infected patients who started antiretroviral therapy based on integrase inhibitorsPurificación Cid-Silva, Luis Margusino-Framiñán, Vanesa Balboa-Barreiro, et al.
AIDS Research and Human Retroviruses|June 3, 2016
Short Communication: Maraviroc Once-Daily: Experience in Routine Clinical PracticeMaria Saumoy, Josep M Llibre, Alberto Terrón, et al.
The Journal of Antimicrobial Chemotherapy|November 15, 2007
Long-distance interactive expert advice in highly treatment-experienced HIV-infected patientsJosep M Llibre, Pere Domingo, Miguel A del Pozo, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|October 17, 2019
Prescription of antimicrobials in primary health care as a marker to identify people living with undiagnosed HIV infection, Denmark, 1998 to 2016Raquel Martin-Iguacel, Court Pedersen, Josep M Llibre, et al.
Pageof 17

Showing results (41-50 of 162) with videos related to

Sort By:
Pageof 17
AIDS Research and Human Retroviruses|December 1, 2010
Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patientsJosé R Santos, Josep M Llibre, Pere Domingo, et al.
Enfermedades Infecciosas Y Microbiologia Clinica|April 11, 2016
Hepatic safety of maraviroc in HIV-1-infected patients with hepatitis C and/or B co-infection. The Maraviroc Cohort Spanish GroupManuel Crespo, Jordi Navarro, Santiago Moreno, et al.
AIDS (London, England)|June 16, 2011
Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapyJosep M Llibre, José R Arribas, Pere Domingo, et al.
AIDS Research and Human Retroviruses|June 9, 2009
How much fat loss is needed for lipoatrophy to become clinically evident?Daniel Podzamczer, Elena Ferrer, Esteban Martínez, et al.
AIDS Reviews|March 18, 2009
HIV-1 genotypic drug resistance interpretation rules - 2009 Spanish guidelinesCarmen de Mendoza, Lourdes Anta, Federico García, et al.
AIDS Research and Human Retroviruses|January 20, 2016
Short Communication: Efficacy and Safety of Treatment Simplification to Lopinavir/Ritonavir or Darunavir/Ritonavir Monotherapy: A Randomized Clinical TrialJosé R Santos, Josep M Llibre, Isabel Bravo, et al.
AIDS (London, England)|November 8, 2017
Initial treatment response among HIV subtype F infected patients who started antiretroviral therapy based on integrase inhibitorsPurificación Cid-Silva, Luis Margusino-Framiñán, Vanesa Balboa-Barreiro, et al.
AIDS Research and Human Retroviruses|June 3, 2016
Short Communication: Maraviroc Once-Daily: Experience in Routine Clinical PracticeMaria Saumoy, Josep M Llibre, Alberto Terrón, et al.
The Journal of Antimicrobial Chemotherapy|November 15, 2007
Long-distance interactive expert advice in highly treatment-experienced HIV-infected patientsJosep M Llibre, Pere Domingo, Miguel A del Pozo, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|October 17, 2019
Prescription of antimicrobials in primary health care as a marker to identify people living with undiagnosed HIV infection, Denmark, 1998 to 2016Raquel Martin-Iguacel, Court Pedersen, Josep M Llibre, et al.
Pageof 17